HERZUMA 150MG VIAL 150 Powder for concentrate for solution for infusion Vial

Product Overview

For comprehensive information and product imagery, you can refer to trusted pharmaceutical e-commerce platforms like Nahdi Online, , or .

Herzuma 150mg Vial contains Trastuzumab, a targeted biological medicine used in the treatment of certain types of cancer.
It is a biosimilar to Herceptin and specifically targets the human epidermal growth factor receptor 2 (HER2) protein, which is overexpressed in some breast and gastric cancers.
This medication is vital in regimens designed to inhibit cancer cell growth and improve patient outcomes.

Benefits of Use

- Targets and inhibits the growth of HER2-positive cancer cells.
- Improves disease-free survival and overall survival rates in eligible patients.
- Often used in combination with chemotherapy to enhance treatment efficacy.
- Provides a well-established treatment option for early and metastatic HER2-positive breast cancer and metastatic HER2-positive gastric cancer.

How to Use

Herzuma is administered by a qualified healthcare professional in a clinical setting. It is not intended for self-administration.
1. The powder in the vial is reconstituted with sterile water for injection, and then diluted into an infusion solution.
2. The prepared solution is administered via intravenous infusion over a specified period.
3. Dosage, frequency, and duration of treatment are determined by your physician based on your specific condition, body weight, and response to therapy.
4. Close monitoring for any infusion-related reactions is crucial during and after administration.

Caution & Warnings

- Herzuma should only be administered under the supervision of a physician experienced in the treatment of cancer.
- Infusion-related reactions, including fever, chills, nausea, vomiting, pain, headache, and rash, can occur. Severe reactions may require discontinuation.
- Cardiotoxicity, including congestive heart failure, has been reported. Cardiac function monitoring (e.g., LVEF assessment) is essential before and during treatment.
- Pulmonary toxicity, such as dyspnea, interstitial pneumonitis, and acute respiratory distress syndrome, has been observed.
- Exposure to Herzuma during pregnancy can cause embryo-fetal toxicity, including oligohydramnios and renal dysfunction. Effective contraception should be used during treatment and for 7 months after the last dose.
- Not recommended for patients with known hypersensitivity to trastuzumab or any excipients.

Ingredients

- Active Ingredient: Trastuzumab (recombinant DNA origin)
- Excipients: L-Histidine, L-Histidine hydrochloride monohydrate, alpha,alpha-Trehalose dihydrate, Polysorbate 20

Product Details

- Form: Powder for concentrate for solution for infusion
- Strength: 150mg
- Package Type: Single-use vial
- Storage: Store in a refrigerator (2°C to 8°C). Do not freeze. Protect from light.
- Manufacturer: Celltrion Healthcare